Clinical Efficacy of CPP-ACP and CPP-ACFP in Xerostomic Patients

Method: The study comprised 30 patients aged 15-54 years randomised into three groups (n=10): CPP-ACP, CPP-ACFP, and 0.05% NaF, to be used two times a day according to the manufacturers’ instructions. The included patients suffered from medical condition associated with xerostomia, had symptoms of dry mouth for longer than 6 months, and the stimulated salivary flow rate lower than 0.7 ml/min. Oral health was evaluated at the beginning of the study, after 28 days (short-term effects) and after 6 months use of CPP-ACP, CPP-ACFP or 0.05% NaF. The diagnosis of dental caries was performed using the DMFT/DFS criteria. To visually examine enamel demineralisation, white spot lesion index (Goerlick) was used. The gingival health, periodontal status and oral hygiene and were assessed with the gingival index (Löe-Silness), CPITN index and the Simplified Oral hygiene index (Greene-Vermilion), respectively. Kruskal-Wallis test, Fisher exact test, and chi-square test were used in the statistical analyses.

Results: During the 6-month experimental period, caries increment was not significant (p>0.05). Considerable regression of white spot lesions was noted in three experimental groups (p<0.001). None of the treatments had effect on gingival/periodontal health and oral hygiene (p>0.05).

Conclusion: CPP-ACP and CPP-ACFP hold promise as caries preventive agents for patients with salivary gland hypofunction.